USD
$0.00
(0.00%
)At Close (As of Nov 28, 2025)
$22.10M
Market Cap
-
P/E Ratio
-0.72
EPS
$3.02
52 Week High
$0.36
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Operating Cashflow | -$27M |
| Payments For Operating Activities | - |
| Proceeds From Operating Activities | - |
| Change In Operating Liabilities | - |
| Change In Operating Assets | - |
| Depreciation Depletion And Amortization | $284K |
| Capital Expenditures | $2K |
| Change In Receivables | - |
| Change In Inventory | - |
| Profit Loss | - |
| Cashflow From Investment | $18M |
| Cashflow From Financing | $27M |
| Proceeds From Repayments Of Short Term Debt | - |
| Payments For Repurchase Of Common Stock | - |
| Payments For Repurchase Of Equity | - |
| Payments For Repurchase Of Preferred Stock | - |
| Dividend Payout | - |
| Dividend Payout Common Stock | - |
| Dividend Payout Preferred Stock | - |
| Proceeds From Issuance Of Common Stock | - |
| Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
| Proceeds From Issuance Of Preferred Stock | - |
| Proceeds From Repurchase Of Equity | - |
| Proceeds From Sale Of Treasury Stock | - |
| Change In Cash And Cash Equivalents | - |
| Change In Exchange Rate | - |
| Net Income | -$25M |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Iterum Therapeutics PLC is a clinical-stage biopharmaceutical company headquartered in Dublin, Ireland, specializing in the development of innovative anti-infective therapies aimed at combating multidrug-resistant infections. With a strong focus on addressing critical unmet medical needs in both the U.S. and European markets, Iterum is strategically positioning itself within the rapidly evolving antimicrobial sector. By prioritizing novel solutions to tackle antibiotic resistance, the company is committed to enhancing patient outcomes and plays a vital role in shaping the future of infectious disease treatment.